Literature DB >> 14733601

Reagents for astatination of biomolecules: comparison of the in vivo distribution and stability of some radioiodinated/astatinated benzamidyl and nido-carboranyl compounds.

D Scott Wilbur1, Ming-Kuan Chyan, Donald K Hamlin, Brian B Kegley, Reudi Risler, Pradip M Pathare, Janna Quinn, Robert L Vessella, Catherine Foulon, Michael Zalutsky, Timothy J Wedge, M Frederick Hawthorne.   

Abstract

An investigation has been conducted to assess the in vivo stability of a series of astatinated benzamides and astatinated nido-carborane compounds in mice. It was hypothesized that the higher bond strength of boron-astatine bonds in the nido-carboranes might provide increased stability toward in vivo deastatination. Four tri-n-butylstannylbenzamides were prepared for radiohalogenation and evaluation in vivo. Those compounds were N-propyl-4-(tri-n-butylstannyl)benzamide 1a, N-propyl-3-(tri-n-butylstannyl)benzamide 2a, ethyl 4-tri-n-butylstannylhippurate 3a, and 4-tri-n-butylstannyl-hippuric acid 4a. Seven mono-nido-carboranyl derivatives were prepared for radiohalogenation and in vivo evaluation. Four of the seven mono-carboranyl derivatives (5a, 6a, 7a, 13a) contained a 3-(nido-carboranyl)propionamide functionality, and the remaining compounds (8a, 8g, 10a) contained a 4-(nido-carboranyl)aniline functionality. Two additional derivatives (11a, 12a) were prepared that contained bis-(nido-carboranylmethyl)benzene moieties (also referred to as Venus flytrap complexes (VFCs). All benzamide and nido-carborane compounds underwent facile iodination and radiohalogenation, except a 4-(nido-carboranyl)aniline derivative, 8a. Iodination of 8a resulted in a mixture, of which the desired iodinated product was a minor component. Therefore, radiohalogenation was not attempted. It is believed that the mixture of products is due to the presence of a thiourea bond. Previous studies have shown that thiourea bonds can interfere with halogenation reactions. In vivo comparisons of the compounds were conducted by co-injection of dual labeled (125/131I and 211At) compounds. Tissue distribution data were obtained at 1 and 4 h postinjection of the radiolabeled compounds, as that was sufficient to determine if astatine was being released. Stability of the astatinated compound was assessed by the difference in concentration of radioiodine and astatine in lung and spleen. All of the benzamides were found to undergo rapid deastatination in vivo. The nido-carborane derivatives appeared to be slightly more stable to in vivo deastatination; however, they had long blood residence times. The surprising finding was that the VFC derivatives did not release 211At in vivo, even though they rapidly localized to liver. This finding provides encouragement that stable conjugates of 211At may be attained if appropriate modifications of the VFC can be made to redirect their excretion through the renal system.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14733601     DOI: 10.1021/bc034175k

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  16 in total

1.  Stability and in vivo behavior of Rh[16aneS4-diol]211 at complex: a potential precursor for astatine radiopharmaceuticals.

Authors:  Marek Pruszyński; Monika Łyczko; Aleksander Bilewicz; Michael R Zalutsky
Journal:  Nucl Med Biol       Date:  2014-12-23       Impact factor: 2.408

2.  A Multi-Functional Tumor Theranostic Nanoplatform for MRI Guided Photothermal-Chemotherapy.

Authors:  Jinjin Shi; Binghua Wang; Zhaoyang Chen; Wei Liu; Jingjing Pan; Lin Hou; Zhenzhong Zhang
Journal:  Pharm Res       Date:  2016-03-16       Impact factor: 4.200

3.  Reagents for astatination of biomolecules. 6. An intact antibody conjugated with a maleimido-closo-decaborate(2-) reagent via sulfhydryl groups had considerably higher kidney concentrations than the same antibody conjugated with an isothiocyanato-closo-decaborate(2-) reagent via lysine amines.

Authors:  D Scott Wilbur; Ming-Kuan Chyan; Hirohisa Nakamae; Yun Chen; Donald K Hamlin; Erlinda B Santos; Brian T Kornblit; Brenda M Sandmaier
Journal:  Bioconjug Chem       Date:  2012-02-10       Impact factor: 4.774

4.  (2S)-2-(3-(1-Carboxy-5-(4-211At-Astatobenzamido)Pentyl)Ureido)-Pentanedioic Acid for PSMA-Targeted α-Particle Radiopharmaceutical Therapy.

Authors:  Ana P Kiess; Il Minn; Ganesan Vaidyanathan; Robert F Hobbs; Anders Josefsson; Colette Shen; Mary Brummet; Ying Chen; Jaeyeon Choi; Eftychia Koumarianou; Kwamena Baidoo; Martin W Brechbiel; Ronnie C Mease; George Sgouros; Michael R Zalutsky; Martin G Pomper
Journal:  J Nucl Med       Date:  2016-05-26       Impact factor: 10.057

5.  Preparation and in vivo evaluation of radioiodinated closo-decaborate(2-) derivatives to identify structural components that provide low retention in tissues.

Authors:  D Scott Wilbur; Ming-Kuan Chyan; Donald K Hamlin; Matthew A Perry
Journal:  Nucl Med Biol       Date:  2010-02       Impact factor: 2.408

6.  Astatine Radiopharmaceuticals: Prospects and Problems.

Authors:  Ganesan Vaidyanathan; Michael R Zalutsky
Journal:  Curr Radiopharm       Date:  2008-09-01

7.  Reagents for astatination of biomolecules. 3. Comparison of closo-decaborate(2-) and closo-dodecaborate(2-) moieties as reactive groups for labeling with astatine-211.

Authors:  D Scott Wilbur; Ming-Kuan Chyan; Donald K Hamlin; Matthew A Perry
Journal:  Bioconjug Chem       Date:  2009-03-18       Impact factor: 4.774

Review 8.  Production of [(211)At]-astatinated radiopharmaceuticals and applications in targeted α-particle therapy.

Authors:  François Guérard; Jean-François Gestin; Martin W Brechbiel
Journal:  Cancer Biother Radiopharm       Date:  2012-10-17       Impact factor: 3.099

9.  Streptavidin in antibody pretargeting. 5. chemical modification of recombinant streptavidin for labeling with the alpha-particle-emitting radionuclides 213Bi and 211At.

Authors:  D Scott Wilbur; Donald K Hamlin; Ming-Kuan Chyan; Martin W Brechbiel
Journal:  Bioconjug Chem       Date:  2007-12-12       Impact factor: 4.774

10.  Preparation of Rh[16aneS4-diol](211)At and Ir[16aneS4-diol](211)At complexes as potential precursors for astatine radiopharmaceuticals. Part I: Synthesis.

Authors:  Marek Pruszyński; Aleksander Bilewicz; Michael R Zalutsky
Journal:  Bioconjug Chem       Date:  2008-03-14       Impact factor: 4.774

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.